TREMFYA
TREMFYA® is a prescription medicine used to treat adults with moderately to severely active ulcerative colitis.
Administration and Dosage:
Ulcerative Colitis:
Induction:
- 200 mg administered by intravenous infusion over at least one hour at Week 0, Week 4, and Week 8.
Maintenance:
- 100 mg administered by subcutaneous injection at Week 16, and every 8 weeks thereafter.
- Or 200 mg administered by subcutaneous injection at Week 12, and every 4 weeks thereafter.
- Use the lowest effective recommended dosage to maintain therapeutic response.
Indication:
TREMFYA is an interleukin-23 antagonist indicated for the treatment of adult patients with:
- Moderately to severely active ulcerative colitis (1.3)
Common Side Effects:
The most common side effects of TREMFYA include:
- Respiratory Tract Infections
- Headache
- Injection Site Reactions
- Joint Pain (Arthralgia)
- Diarrhea
- Stomach Flu (Gastroenteritis)
- Fungal Skin Infections
- Herpes Simplex Infections
- Bronchitis
These are not all the possible side effects of TREMFYA. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
More information:
Please read the full Prescribing Information and Patient Information for TEPEZZA® and discuss any questions you have with your doctor.
HAVE QUESTIONS?
We are happy to help!
